Drug Profile
Research programme: hypersensitivity therapeutics - Biomay
Alternative Names: Allergen-specific immunotherapy adjuvant - Biomay; Anti-IgE - Biomay; BM 31; BM 34; BM 35; BM 36; Carbohydrate particle based adjuvant - Biomay; Cell-based tolerance induction - Biomay; Immunomodulating adjuvant - Biomay; RNA vaccination - BiomayLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Biomay
- Class Cell therapies; RNA; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity; Ragweed pollen hypersensitivity; Tree pollen hypersensitivity
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Allergy in Austria
- 28 Jan 2018 No recent reports of development identified for preclinical development in Ragweed pollen hypersensitivity in Austria
- 28 Jan 2018 No recent reports of development identified for preclinical development in Tree pollen hypersensitivity in Austria